Several things patients must know when taking the drug: What are the warnings and precautions for ivonib?

During clinical studies of Ivosidenib (Ivosidenib), warnings and precautions such as acute myeloid leukemia and myelodysplastic syndrome differentiation syndrome, QTc interval prolongation, Guillain-Barré syndrome, etc. have emerged. Discontinue and resume at reduced dose upon recovery, or permanently discontinue based on severity.

1. Differentiation syndrome of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): Differentiation syndrome is related to the rapid proliferation and differentiation of bone marrow cells and may be life-threatening or fatal. Symptoms of differentiation syndrome in patients receiving ivosidenib include noninfectious leukocytosis, peripheral edema, pyrexia, dyspnea, pleural effusion, hypotension, hypoxia, pulmonary edema, pneumonia, pericardial effusion, rash, fluid overload, tumor lysis syndrome, and elevated creatinine, which may occur as early as 1 day to 3 months after initiation of treatment, with or without leukocytosis.

If differentiation syndrome is suspected, initiate dexamethasone 10 mg intravenously every 12 hours (or an equivalent dose of an alternative oral or intravenous corticosteroid) and monitor hemodynamics until symptoms improve. If concomitant noninfectious leukocytosis is observed, initiate treatment with hydroxyurea or leukapheresis as clinically indicated. After symptoms resolve, gradually reduce the dosage of corticosteroids and hydroxyurea and continue taking corticosteroids for at least 3 days. Premature discontinuation of corticosteroid and/or hydroxyurea therapy may result in recurrence of differentiation syndrome symptoms. If severe signs and/or symptoms persist more than 48 hours after starting corticosteroids, interrupt ivosidenib until signs and symptoms are no longer severe.

2. QTc interval prolongation: QT (QTc) prolongation and ventricular arrhythmias may occur in patients receiving ivonib treatment. Coadministration of ivonib with drugs known to prolong the QTc interval (e.g., antiarrhythmic drugs, fluoroquinolones, triazole antifungals, 5-HT3 receptor antagonists) and CYP3A4 inhibitors may increase the risk of QTc interval prolongation. Monitor electrocardiogram (ECG) and electrolytes. More frequent monitoring may be necessary in patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking drugs known to prolong the QTc interval.

IfQTc increases to >480msec or <500msec, interrupt ivosidenib. If QTc increases above 500 msec, interrupt and reduce ivonib. Ivonib should be permanently discontinued in patients who develop QTc prolongation with signs or symptoms of life-threatening arrhythmias.

3. Green-Guillain-Barré Syndrome: Monitor patients taking ivosidenib for new signs or symptoms of motor and/or sensory neuropathy, such as unilateral or bilateral weakness, sensory changes, paresthesia, or dyspnea. Patients diagnosed with Guillain-Barré syndrome should permanently discontinue ivosidenib.